688180 君實生物
按盤價 
24.470 +0.140 (+0.575%) | 2024/06 - 中期 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | 盈利能力分析 |
| 淨資產收益率 ROE (%) | -9.464 | -27.454 | -27.404 | -10.469 | -37.900 |
| 總資產報酬率 ROA (%) | -5.776 | -19.107 | -20.243 | -7.576 | -26.893 |
| 投入資產回報率 ROIC (%) | -6.915 | -22.727 | -24.558 | -9.379 | -31.453 | 邊際利潤分析 |
| 銷售毛利率 (%) | 73.231 | 63.996 | 65.304 | 69.079 | 76.642 |
| 營業利潤率 (%) | -85.959 | -163.551 | -183.414 | -13.871 | -103.836 |
| 息稅前利潤/營業總收入 (%) | -87.155 | -170.296 | -189.759 | -14.004 | -103.533 |
| 淨利潤/營業總收入 (%) | -87.489 | -168.759 | -177.784 | -18.151 | -104.622 | 收益指標分析 |
| 經營活動淨收益/利潤總額(%) | 94.816 | 92.680 | 98.964 | 118.222 | 102.386 |
| 價值變動淨收益/利潤總額(%) | 8.768 | 3.018 | 1.913 | -11.050 | -2.417 |
| 營業外收支淨額/利潤總額(%) | 1.238 | 1.375 | 0.421 | 6.172 | 0.977 | 償債能力分析 |
| 流動比率 (X) | 2.109 | 2.285 | 4.086 | 2.920 | 3.191 |
| 速動比率 (X) | 1.866 | 2.064 | 3.746 | 2.678 | 2.958 |
| 資產負債率 (%) | 39.899 | 35.461 | 22.153 | 24.636 | 27.129 |
| 帶息債務/全部投入資本 (%) | 27.062 | 18.739 | 10.697 | 5.317 | 11.260 |
| 股東權益/帶息債務 (%) | 255.338 | 411.315 | 819.634 | 1,731.442 | 767.704 |
| 股東權益/負債合計 (%) | 147.748 | 177.791 | 340.888 | 292.256 | 268.612 |
| 利息保障倍數 (X) | 736.176 | 38.142 | 34.070 | -17.970 | -77.939 | 營運能力分析 |
| 應收賬款周轉天數 (天) | 106.839 | 86.422 | 189.637 | 84.232 | 85.044 |
| 存貨周轉天數 (天) | 467.135 | 378.341 | 386.772 | 119.759 | 253.231 |
| 備註： | 即時報價更新時間為 19/09/2024 16:29 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
